E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 1/7/2020 in the Prospect News Structured Products Daily.

New Issue: JPMorgan sells $1.17 million contingent interest autocalls on pharma stocks

By Wendy Van Sickle

Columbus, Ohio, Jan. 7 – JPMorgan Chase Financial Co. LLC priced $1.17 million of autocallable contingent interest notes due Dec. 30, 2022 linked to the least performing of the common stocks of McKesson Corp., Gilead Sciences, Inc. and Pfizer Inc., according to a 424B2 filing with the Securities and Exchange Commission.

The notes are guaranteed by JPMorgan Chase & Co.

The notes will pay a contingent quarterly coupon at an annual rate of 10% if each stock closes at or above its interest barrier level, 55% of its initial level, on the review date for that quarter.

The notes will be called at par plus the contingent coupon if each stock closes at or above its initial level on any quarterly review date other than the first and final date.

The payout at maturity will be par plus the final coupon unless any stock finishes below its 55% barrier level, in which case investors will lose 1% for each 1% decline of the worse performing stock from its initial level.

J.P. Morgan Securities LLC is the agent.

Issuer:JPMorgan Chase Financial Co. LLC
Guarantor:JPMorgan Chase & Co.
Issue:Autocallable contingent interest notes
Underlying stocks:McKesson Corp., Gilead Sciences, Inc., Pfizer Inc.
Amount:$1,166,000
Maturity:Dec. 30, 2022
Coupon:10% annualized, payable quarterly if each underlying stock closes at or above barrier level on review date for that quarter
Price:Par
Payout at maturity:Par plus final coupon unless any stock finishes below barrier level, in which case 1% loss for each 1% decline of worse performing stock from initial level
Call:At par plus contingent coupon if each stock closes at or above initial level on any quarterly review date other than the first and final date
Initial levels:$139.44 for McKesson, $65.95 for Gilead Sciences and $39.32 for Pfizer
Interest/barrier levels:$76.692 for McKesson, $36.2725 for Gilead Sciences and $21.626 for Pfizer; 55% of initial levels
Pricing date:Dec. 27
Settlement date:Dec. 31
Agent:J.P. Morgan Securities LLC
Fees:2.5%
Cusip:48132HKT8

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.